Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human ...

It's encouraging to think that multiple startups will find ways to leverage AI and other fields to accelerate drug discovery and improve patient outcome.

Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion ...

SALT LAKE CITY, Nov. 20, 2024-- The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly ...

Recursion Pharmaceuticals , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia for $688 million in an all-stock deal ...

Recursion Pharmaceuticals had a busy start to the week, scrapping a rare disease asset from its pipeline as part of a strategic rethink while pulling in a $150 million private placement.

Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.